Advertisement

Pharmacological Interventions

  • Keith Cheng
  • Kathleen Myers

Abstract

The use of psychotropic medications has increasingly become part of comprehensive treatment plans for children and adolescents. Due to the paucity of research, however, pediatric psychopharmacology is more an art than a science. Most rigorous pharmacological studies have focused on attention-deficit hyperactivity disorder (ADHD), and there are clear indications for stimulants as the primary therapy. However, there are fewer and less rigorous well controlled studies of antidepressants in children and adolescents, and even fewer in number and less well designed studies of antianxiety or anxiolytic medications. Thus, recommendations for using them in treatment are not as clear as for ADHD. Despite the lack of rigorous data, psychotropics are increasingly used. Factors contributing to this trend are diverse, including increasing severity of juvenile psychopathology, school mandates to educate youths who have serious psychiatric disorders, parents, and the inability of communities to manage their children's problems sufficiently, lack of appropriate alternative services, the availability of more effective medications that have relatively benign side effects, and pressure to contain costs from managed care.

Keywords

Anxiety Disorder American Academy Psychotropic Medication Atypical Antipsychotic Antipsychotic Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Addington, D. E., Jones, B., Bloom, D., Chouinard, G., Remington, G., & Albright, P. (1993). Reduction of hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study. Clinical Therapy, 15, 917–926.Google Scholar
  2. Akiskal, H. S., Downs, J., Jordan, P., Watson, S., Daugherty, D., & Pruitt, D. B. (1985). Affective disorders in referred children and younger siblings of manic depressives. Archives of General Psychiatry, 42, 996–1003.PubMedCrossRefGoogle Scholar
  3. American Academy of Pediatrics, Committee on Bioethics (1995). Informed consent, parental permission, and assent in pédiatrie practice. Pediatrics, 95, 314–317.Google Scholar
  4. Bernstein, G., Borchard, C, & Perwein, A. (1996). Anxiety disorders in children and adolescents: A review of the past ten years. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1110–1119.PubMedCrossRefGoogle Scholar
  5. Biederman, J., Thisted, R. A., Greenhill, L. L., & Ryan, N. D. (1995). Estimation of the association between desipramine and the risk for sudden death in 5-to 14-year-old children. Journal of Clinical Psychiatry, 56, 87–93.PubMedGoogle Scholar
  6. Birmaher, B., Ryan, N. D., Williamson, D. E., Brent, D. A., Kaufman, J., Dahl, R. E., Perel, J., & Nelson, B. (1996a). Childhood and adolescent depression: A review of the past 10 years. Part I. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1427–1439.PubMedCrossRefGoogle Scholar
  7. Birmaher, B., Ryan, N. D., Williamson, D. E., Brent, D. A., & Kaufman, J. (1996b). Childhood and adolescent depression: A review of the past 10 years. Part II. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1575–1583.PubMedCrossRefGoogle Scholar
  8. Birmaher, B., Waterman, G. S., Ryan, N., Cully, M., Balach, L., Ingram, J., & Brodsky, M. (1994). Fluoxetine for childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 993–999.PubMedCrossRefGoogle Scholar
  9. Bradley, C. (1937). Behavior of children receiving benzedrine. American Journal of Psychiatry, 94, 577–585.Google Scholar
  10. Campbell, M., Silva, R. R., Kafantaris, V., Locascio, J. J., Gonzalez, N. M., Lee, D., & Lynch, N. S. (1991). Predictors of side effects associated with lithium administration in children. Psychopharmacology Bulletin, 27, 373–380.PubMedGoogle Scholar
  11. Cantwell, D. P. (1996). Attention deficit disorder: A review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 978–987.PubMedCrossRefGoogle Scholar
  12. Cantwell, D. P., Swanson, J., & Conners, D. F. (1997). Case study: Adverse response to clonidine. Journal of the American Academy of Child and Adolescent Psychiatry, 36(4), 539–544.PubMedCrossRefGoogle Scholar
  13. Carlson, G. A., & Weintraub, S. (1993). Childhood behavior problems and bipolar disorder: Relationship or coincidence? Journal of Affective Disorders, 28, 143–153.PubMedCrossRefGoogle Scholar
  14. Carrey, N. J., Wiggins, D. M., & Milin, R. P. (1996). Pharmacological treatment of psychiatric disorders in children and adolescents: Focus on guidelines for the primary care practitioner. Drugs, 51, 750–759.PubMedCrossRefGoogle Scholar
  15. Cauffman, E., & Steinberg, L. (1995). The cognitive and affective influences on adolescent decision making. Temple Law Review, 68, 1763–1789.Google Scholar
  16. Chappell, P. B., Riddle, M. A., Scahill, L., Lynch, K. A., Schultz, R., Arnsten, A., Leckman, J. F., & Cohen, D. J. (1995). Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: Preliminary clinical experience. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1140–1146.PubMedCrossRefGoogle Scholar
  17. Committee on Bioethics (1995). Informed consent, parental permission, and assent in pédiatrie practice. The American Academy of Pediatrics, 95, 314–317.Google Scholar
  18. Conners, C. K., Casat, C. D., Gualtieri, C. T., Weller, E., Reader, M., Reiss, A., Weller, R. A., Khayrallah, M., & Ascher, J. (1996). Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1314–1321.PubMedCrossRefGoogle Scholar
  19. Dahl, R. E., Ryan, N. D., Puig-Antich, J., Nguyen, N. A., al-Shabbout, M, Meyer, V. A., & Perel, J. (1991). 24-hour cortisol measures in adolescents with major depression: A controlled study. Biological Psychiatry, 30(1), 25–36.PubMedCrossRefGoogle Scholar
  20. DeVaugh-Geiss, J., Moroz, G., Biederman, J., Cantwell, D., Fontaine, R., Greist, J. H., Reichler, R., Katz, R.,’ Landau, P. (1992). Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: A multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 45–49.CrossRefGoogle Scholar
  21. Dulcan, M. (1997). Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 56(10 Supplement), 85S–121S.Google Scholar
  22. Emslie, G. J., Rush, A. J., Weinberg, W. A., Kowatch, R. A., Hughes, C. W., Carmody, T., & Rintelmann, J. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54, 1031–1307.PubMedCrossRefGoogle Scholar
  23. Famularo, R., Kinscherff, R., & Fenton, T. (1988). Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. American Journal of Diseases of Children, 142, 1244–1247.PubMedGoogle Scholar
  24. Faraone, S. V., Biederman, J., Wozniak, J., Mundy, E., Mennin, D., & O’Donnell, D. (1997). Is comorbidity with ADHD a marker for juvenile-onset mania? Journal of the American Academy of Child and Adolescent Psychiatry, 36, 1046–1055.PubMedCrossRefGoogle Scholar
  25. Feldman, H., Crumrine, P., Handen, B. L., Alvin, R., & Teodori, J. (1989). Methylphenidate in children with seizures and attention-deficit disorder. American Journal of Diseases of Children, 143, 1081–1086.PubMedGoogle Scholar
  26. Ferreri, M., & Hantouche, E. G. (1998). Recent trials of hydroxyzine in generalized anxiety disorder. Ada Psychiatrica Scandinavica, Supplementum, 393, 102–108.CrossRefGoogle Scholar
  27. Gadow, K. D., Sverd, J., Sprafkin, J., Nolan, E. E., & Grossman, S. (1999). Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry, 56, 330–336.PubMedCrossRefGoogle Scholar
  28. Garland, E. J. (1998). Intranasal abuse of prescribed methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 1242–1243.PubMedCrossRefGoogle Scholar
  29. Geller, B. (1997). Double-blind placebo-controlled study of lithium for adolescents with comorbid bipolar and substance dependency disorders. Presented at the Annual Midyear Institute of the American Academy of Child and Adolescent Psychiatry, March 19-21, Hamilton, Bermuda.Google Scholar
  30. Geller, B., Cooper, T. B., Chestnut, E. C, Abel, A. S., & Anker, J. A. (1984). Nortriptyline pharmacokinetic parameters in depressed children and adolescents: Preliminary data. Journal of Clinical Psychopharmacology, 4, 265–269.PubMedCrossRefGoogle Scholar
  31. Geller, B., Cooper, T. B., & Chestnut, E. C. (1985). Serial monitoring and achievement of steady state nortriptyline plasma levels in depressed children and adolescents: Preliminary data. Journal of Clinical Psychopharmacology, 5, 213–216.PubMedGoogle Scholar
  32. Geller, B., Cooper, T. B., Zimerman, B., Sun, K., Williams, M., & Frazier, J. (1994a). Double-blind placebo-controlled study of lithium for depressed children with bipolar family histories. Neumpsychopharmacology, 10(S-122), 541S.Google Scholar
  33. Geller, B., & Fetner, H. H. (1989). Children’s 24-hour serum lithium level after a single dose predicts initial dose and steady-state plasma level. Journal of Clinical Psychopharmacology, 9, 155.PubMedCrossRefGoogle Scholar
  34. Geller, B., Fox, L. W., & Clark, K. A. (1994b). Rate and predictors of prepubertal bipolarity during follow-up of 6-to 12-year-old depressed children. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 461–468.PubMedCrossRefGoogle Scholar
  35. Geller, B., Fox, L. W., & Fletcher, M. (1993). Effect of tricyclic antidepressants on switching to mania and on the onset of bipolarity in depressed 6-to 12-year-olds. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 43–50.PubMedCrossRefGoogle Scholar
  36. Geller, B., & Luby, J. (1997). Child and adolescent bipolar disorder: A review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 1168–1176.PubMedCrossRefGoogle Scholar
  37. Geller, B., Sun, K., Zimmerman, B., Luby, J., Frazier, J., & Williams, M. (1995). Complex and rapid-cycling in bipolar children and adolescents: A preliminary study. Journal of Affective Disorders, 34, 259–268.PubMedCrossRefGoogle Scholar
  38. Goldman-Rakic, C. P., & Brown, R. M. (1982). Postnatal development of monoamine content and synthesis in the cerebral cortex of rhesus monkeys. Developmental Brain Research, 4, 339–349.CrossRefGoogle Scholar
  39. Grcevich, S. J., Findling, R. L., Rowane, W. A., Friedman, L., & Schulz, S. C. (1996). Risperidone in the treatment of children and adolescents with schizophrenia: A retrospective study. Journal of Child and Adolescent Psychopharmacology, 6, 251–257.PubMedCrossRefGoogle Scholar
  40. Gutgesell, H., Atkins, D., Barst, R., Buck, M., Franklin, W, Humes, R., Ringel, R., Shaddy, R., & Taubert, K. A. (1999). Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. Circulation, 99, 979–982.PubMedCrossRefGoogle Scholar
  41. Hagino, O. R., Weiler, E. B., Weiler, R. A., Washing, D., Fristad, M. A., & Kontras, S. B. (1995). Untoward effects of lithium treatment in children aged four through six years. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1584–1590.PubMedCrossRefGoogle Scholar
  42. Hanna, G. L., Feibusch, E. L., & Albright, K. J. (1997). Buspirone treatment of anxiety associated with pharyngeal dysphasia in a four-year-old. Journal of the American Academy of Child and Adolescent Psychiatry, 7137–143.Google Scholar
  43. Harmon, R. J., & Riggs, P. D. (1996). Clonidine for posttraumatic stress disorder in preschool children. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1247–1249.PubMedCrossRefGoogle Scholar
  44. Horrigan, J. P. (1996). Guanfacine for PTSD nightmares. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 975–976.PubMedCrossRefGoogle Scholar
  45. Hyman, S. E., & Nestler, E. J. (1996). Initiation and adaptation: A paradigm for understanding psychotropic drug action. American Journal of Psychiatry, 153, 151–162.PubMedGoogle Scholar
  46. Isojarvi, J. I., Laatikainen, T. J., Pakarinen, A. J., Juntunen, K. T., & Myllyla, V. V. (1993). Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. New England Journal of Medicine, 329, 1383–1388.PubMedCrossRefGoogle Scholar
  47. Jakala, P., Riekkinen, M., Sirvio, J., Koivisto, E., Kejonen, K., Vanhanen, M, & Riekkinen, P., Jr. (1999). Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neumpsychopharmacology, 20, 460–470.CrossRefGoogle Scholar
  48. Joshi, P. T., Hamel, L., Joshi, A. R., & Capozzoli, J. A. (1998). Use of droperidol in hospitalized children. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 228–230.PubMedCrossRefGoogle Scholar
  49. Kelly, D. L., Conley, R. R., Love, R. C, Horn, D. S., & Ushchak, C. M. (1998). Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. Journal of Child and Adolescent Psychopharmacology, 8, 151–159.PubMedCrossRefGoogle Scholar
  50. King, R. A., Riddle, M. S., Chappell, P. B., Hardin, M. T., Anderson, G. M, Lombroso, P., & Scahill, L. (1991). Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 179–186.PubMedCrossRefGoogle Scholar
  51. Kingsbury, S. J., & Tekell, J. L. (1999). What are the advantages and disadvantages of using different providers for psychotherapy and drug treatment? Harvard Mental Health Letter, 15(11), 8.PubMedGoogle Scholar
  52. Kolmen, B. K., Feldman, H. M., Handen, B. L., & Janosky, J. E. (1995). Naltrexone in young autistic children: A double-blind, placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 223–231.PubMedCrossRefGoogle Scholar
  53. Kovacs, M., & Gatsonis, C. (1994). Secular trends in age at onset of major depressive disorder in a clinical sample of children. Journal of Psychiatric Research, 28, 319–329.PubMedCrossRefGoogle Scholar
  54. Kovacs, M., & Pollock, M. (1995). Bipolar disorder and comorbid conduct disorder in childhood and adolescence. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 715–723.PubMedCrossRefGoogle Scholar
  55. Kuperman, S., & Stewart, M. A. (1987). Use of propranolol to decrease aggressive outbursts in younger patients. Open study reveals potentially favorable outcome. Psychosomatics, 28, 315–319.PubMedCrossRefGoogle Scholar
  56. Leonard, H. L., March, J., Rickler, K. C, & Allen, A. J. (1997). Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 725–736.PubMedCrossRefGoogle Scholar
  57. Leonard, H. L., Meyer, M. C, Swedo, S. E., Richter, D., Hamburger, S. D., Allen, A. J., Rapoport, J. L., & Tucker, E. (1995). Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1460–1468.PubMedCrossRefGoogle Scholar
  58. Lombroso, P. J., Scahill, L., King, R. A., Lynch, K. A., Chappell, P. B., Peterson, B. S., McDougle, C. J., & Leckman, J. F. (1995). Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1147–1152.PubMedCrossRefGoogle Scholar
  59. March, J., Biederman, J., Wolkow, R., & Safferman, A. (1998). Sertraline in children and adolescents with obsessive compulsive disorder: A multicenter double-blind placebo-controlled study. Journal of the American Medical Association, 280, 1752–1756.PubMedCrossRefGoogle Scholar
  60. March, J. S., Kobak, K. A., Jefferson, J. W., Mazza, J., & Greist, J. H. (1990). A double-blind, placebo-controlled trial of fluroxamine versus impramine in outpatients with major depression. Journal of Clinical Psychiatry, 51, 200–202.PubMedGoogle Scholar
  61. Myers, K., & McCauley, E. (1997). Treatment of depressive disorders during adolescence. In D. L. Dunner (Ed.), Current psychiatric therapy II, 2nd ed. (pp. 458–467). Philadelphia: W.B. Saunders.Google Scholar
  62. Neumann, P. J. (1999). Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: Implications for schizophrenia treatment. Journal of Clinical Psychology, 60(Suppl 3), 9–14, discussion 15.Google Scholar
  63. Papatheodorou, G., & Kutcher, S. P. (1993). Divalproex sodium treatment in late adolescent and young adult acute mania. Psychopharmacology, 29, 213–219.Google Scholar
  64. Pfeffer, C. R., Jiang, H., & Domeshek, L. J. (1997). Buspirone treatment of psychiatrically hospitalized prepubertal children with symptoms of anxiety and moderately severe aggression. Journal of Child and Adolescent Psychopharmacology, 7, 145–155.PubMedCrossRefGoogle Scholar
  65. Pizzuti, D. (1999, June). Cylert (pemoline) patient information/consent form. Abbott Pharmaceutical Products Division, 99F–110–6993A.Google Scholar
  66. Preskorn, S. H., Bupp, S. J., Weiler, E. B., & Weiler, R. A. (1989). Plasma levels of imipramine and metabolites in 68 hospitalized children. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 373–375.PubMedCrossRefGoogle Scholar
  67. Richman, N. (1985). A double-blind drug trial of treatment in young children with waking problems. Journal of Child Psychology and Psychiatry and Allied Disciplines, 26, 591–598.CrossRefGoogle Scholar
  68. Riddle, M. A., Brown, N., Dzubinski, D., Jetmalani, A. N., Law, Y., & Woolston, J. L. (1989). Fluoxetine overdose in an adolescent. Journal of the American Academy of Child and Adolescent Psychiatry, 23, 587–588.CrossRefGoogle Scholar
  69. Riddle, M. A., Claghorn, J., Gaffney, G., et al. (1996). Fluvoxamine for children and adolescents with OCD: A controlled multicenter trial. Presented at the 43rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 25, Philadelphia.Google Scholar
  70. Riddle, M. A., Nelson, J. C, Kleinman, C. S., Rasmusson, A., Leckman, J. F., King, R. A., & Cohen, D. J. (1991). Sudden death in children receiving Norpramin: A review of three reported cases and commentary. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 104–108.PubMedCrossRefGoogle Scholar
  71. Riddle, M. A., Scahill, L., King, R. A., Hardin, M. T., Anderson, G. M., Ort, S. I., Smith, J. C, Leckman, J. F., & Cohen, D. J. (1992). Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 1062–1069.PubMedCrossRefGoogle Scholar
  72. Rosenberg, D. R., Stewart, C. M., Fitzgerald, K. D., Tawile, V., & Carroll, E. (1999). Paroxetine open-label treatment of pédiatrie outpatients with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1180–1185.PubMedCrossRefGoogle Scholar
  73. Rosenheck, R., Cramer, J., Allan, E., Erdos, J., Frisman, L. K., Xu, W., Thomas, J., Henderson, W., & Charney, D. (1999). Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on clozapine in refractory schizophrenia. Archives of General Psychiatry, 56, 565–572.PubMedCrossRefGoogle Scholar
  74. Ryan, N. D. (1992). The pharmacologie treatment of child and adolescent depression. Psychiatric Clinics of North America, 15, 29–40.PubMedGoogle Scholar
  75. Ryan, N. D., Williamson, D. E., Iyengar, S., Orvaschel, H., Reich, T., Dahl, R. E., & Puig-Antich, J. (1992). A secular increase in child and adolescent onset affective disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 600–605.PubMedCrossRefGoogle Scholar
  76. Safer, D. J., Zito, J. M., & Fine, E. M. (1996). Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics, 98, 1084–1088.PubMedGoogle Scholar
  77. Schowalter, J. E. (1989). Psychodynamics and medication. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 681–684.PubMedCrossRefGoogle Scholar
  78. Schreier, H. A. (1998). Risperidone for young children with mood disorders and aggressive behavior. Journal of Child and Adolescent Psychopharmacology, 8(1), 49–59.PubMedCrossRefGoogle Scholar
  79. Silva, R. R., Munoz, D. M, & Alpert, M. (1996). Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: A meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 352–358.PubMedCrossRefGoogle Scholar
  80. Simeon, J., Dinicola, V. B., Ferguson, H. B., & Copping, W. (1990). Adolescent depression: A placebo controlled fluoxetine treatment study and follow-up. Progress in Neuropsychopharmacology and Biological Psychiatry, 14, 791–795.CrossRefGoogle Scholar
  81. Stein, D. J., Bouwer, C, Hawkridge, S., & Emsley, R. A. (1997). Risperidone augmentation of SSRIs in obsessive compulsive and related disorders. Journal of Clinical Psychiatry, 58(3), 119–122.PubMedCrossRefGoogle Scholar
  82. Strober, M. (1992). Relevance of early age-of-onset in genetic studies of bipolar affective disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 606–610.PubMedCrossRefGoogle Scholar
  83. Strober, M., Freeman, R., Rigali, J., Schmidt, S., & Diamond, R. (1992). The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine. Journal of the American cademy of Child and Adolescent Psychiatry, 31, 16–20.CrossRefGoogle Scholar
  84. Strober, M., Lampert, C, Schmidt, S., & Morrell, W. (1993). The course of major depressive disorder in adolescents: I. Recovery and risk of manic switching in a follow-up of psychotic and nonpsychotic subtypes. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 34–42.PubMedCrossRefGoogle Scholar
  85. Strober, M., Morrell, W., Burroughs, J., Lampert, C, Danforth, H., & Freeman, R. (1988). A family study of bipolar I disorder in adolescence: Early onset of symptoms linked to increased familial loading and lithium resistance. Journal of Affective Disorders, 15, 255–268.PubMedCrossRefGoogle Scholar
  86. Strober, M., Morrell, W., Lampert, C, & Burroughs, J. (1990). Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness: A naturalistic study. American Journal of Psychiatry, 147, 457–461.PubMedGoogle Scholar
  87. Strober, M., Schmidt-Lackner, S., Freeman, R., Bower, S., Lampert, C, & DeAntonio, M. (1995). Recovery and relapse in adolescents with bipolar affective illness: A five-year naturalistic prospective follow-up. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 724–731.PubMedCrossRefGoogle Scholar
  88. Thomas, C. R., & Holzer, C. E. (1999). National distribution of child adolescent psychiatrists. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 9–15.PubMedCrossRefGoogle Scholar
  89. Varley, C. K., & McClellan, J. (1997). Case study: Two additional sudden deaths with tricyclic antidepressants. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 390–394.PubMedCrossRefGoogle Scholar
  90. Wagner, K. D. (1999). Multisite study of paroxetine versus imipramine and placebo in the treatment of children and adolescents with major depression. Paper presented at Oregon Health Sciences University, June 18.Google Scholar
  91. Walsh, B. T, Greenhill, L. L., Giardina, E. V., Bigger, J. T., Waslick, B. D., Sloan, R. P., Bilich, K., Wölk, S., &Google Scholar
  92. Bagiella, E. (1999). Effects of desipramine on autonomie input to the heart. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1186–1192.PubMedCrossRefGoogle Scholar
  93. Weiss, G., Hechtman, L., Milroy, T., & Perlman, T. (1985). Psychiatric status of hyperactives as adults: A controlled prospective 15-year follow-up of 63 hyperactive children. Journal of the American Academy of Child and Adolescent Psychiatry, 24, 211–220.CrossRefGoogle Scholar
  94. Weithorn, L. A., & Campbell, S. B. (1982). The competency of children and adolescents to make informed treatment decisions. Child Development, 53, 1597–1598.CrossRefGoogle Scholar
  95. Weiler, E. B., Weller, R. A., & Fristad, M. A. (1995). Bipolar disorder in children: Misdiagnosis, underdiagnosis, and future directions. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 709–714.CrossRefGoogle Scholar
  96. Werry, J. S., & Aman, M. G. (1999). Practitioner’s guide to psychoactive drugs for children and adolescents, 2nd ed. New York: Plenum Medical Book.Google Scholar
  97. West, S. A., McElroy, S. L., Strkowski, S. M., Keck, P. E., Jr., & McConville, B. J. (1995). Attention deficit hyperactivity disorder in adolescent mania. American Journal of Psychiatry, 152, 271–273.PubMedGoogle Scholar
  98. Wilens, T. E., Spencer, T. J., Swanson, J. M., Connor, D. F, & Cantwell, D. (1999). Combining methylphenidate and clonidine: A clinically sound medication option. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 614–619, discussion 619-622.PubMedCrossRefGoogle Scholar
  99. Wilens, T. E., Biederman, J., Baldessarini, R. J., Geller, B., Schleifer, D., Spencer, T. J., Birmaher, B., & Goldblatt, A. (1996). Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1491–1501.PubMedCrossRefGoogle Scholar
  100. Wilens, T. E., Biederman, J., Baldessarini, R. J., Puopolo, P. R., & Flood, J. G. (1992). Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 691–698.PubMedCrossRefGoogle Scholar
  101. Williams, D. T., Mehl, R., Yudofsky, S., Adams, D., & Roseman, B. (1982). The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. Journal of the American Academy of Child and Adolescent Psychiatry, 21, 129–135.CrossRefGoogle Scholar
  102. Wirshing, D. A., Wirshing, W. C, Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999). Novel antipsychotics: Comparison of weight gain liabilities. Journal of Clinical Psychiatry, 60, 358–363.PubMedCrossRefGoogle Scholar
  103. Wozniak, J., Biederman, J., Kiely, K., Ablon, J. S., Faraone, S. V., Mundy, E., & Mennin, D. (1995). Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 867–876.PubMedCrossRefGoogle Scholar
  104. Yudofsky, S., Williams, D., & Gorman, J. (1981). Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes. American Journal of Psychiatry, 138, 218–220.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Keith Cheng
    • 1
  • Kathleen Myers
    • 2
  1. 1.Child and Adolescent Treatment ProgramEmanuel HospitalPortlandUSA
  2. 2.Outpatient Child and Adolescent Psychiatry, Department of PsychiatryOregon Health Sciences UniversityPortlandUSA

Personalised recommendations